ReviewJournal of mammary gland biology and neoplasia2001
TGF-beta signaling in mammary gland development and tumorigenesis.
Review in Journal of mammary gland biology and neoplasia, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 99 citations in OpenAlex.
- Influence of Pregnancy on Whole-Transcriptome Sequencing in the Mammary Gland of Kazakh Mares.Animals : an open access journal from MDPI · 2025Article
- Article
- Epigenetic identification of LTBP4 as a putative tumor suppressor in breast cancer.Epigenomics · 2024Article
- Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis.American journal of physiology. Cell physiology · 2022Review
- Cytokine Expression in Canine Lymphoma, Osteosarcoma, Mammary Gland Tumour and Melanoma: Comparative Aspects.Veterinary sciences · 2019Review
- TGF-β Family Signaling in Ductal Differentiation and Branching Morphogenesis.Cold Spring Harbor perspectives in biology · 2018Review
- Decrease of lactogenic hormones induce epithelial-mesenchymal transition via TGFβ1 and arachidonic acid during mammary gland involution.The Journal of reproduction and development · 2017Article
- Overexpression of HOXB7 protein reduces sensitivity of oral cancer cells to chemo-radiotherapy.Cancer gene therapy · 2016Article
- Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.BMC cancer · 2016Article
- Chamaejasmenin B, a novel candidate, inhibits breast tumor metastasis by rebalancing TGF-beta paradox.Oncotarget · 2016Article
- TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.BMC cancer · 2015Article
- HOXB7 promotes malignant progression by activating the TGFβ signaling pathway.Cancer research · 2015Article
- Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling.Oncogene · 2014Article
- Transforming growth factor beta1 (TGFβ1) polymorphisms and breast cancer risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion.Oncogene · 2013Article
- Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.PloS one · 2013Article
- Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner.Molecular cancer research : MCR · 2012Article
- Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity.Breast cancer research : BCR · 2012Review
- Phosphorylation of ΔNp63α via a novel TGFβ/ALK5 signaling mechanism mediates the anti-clonogenic effects of TGFβ.PloS one · 2012Article
- FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.Development (Cambridge, England) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ligands of the TGF-beta superfamily are unique in that they signal through transmembrane receptor serine-threonine kinases, rather than tyrosine kinases. The receptor complex couples to a signal transduction pathway involving a novel family of proteins, the Smads. On phosphorylation, Smads translocate to the nucleus where they modulate transcriptional responses. However, TGF-betas can also activate the mitogen-activated protein kinase (MAPK)4 pathway, and the different biological responses to TGF-beta depend to varying degrees on activation of either or both of these two pathways. The Smad pathway is a nexus for cross-talk with other signal transduction pathways and for modulation by many different interacting proteins. Despite compelling evidence that TGF-beta has tumor suppressor activity in the mammary gland, neither TGF-beta receptors nor Smads are genetically inactivated in human breast cancer, though receptor expression is reduced. Possible reasons are discussed in relation to the dual role of TGF-beta as tumor suppressor and oncogene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.